Multi-Center, Double-Blind, Vehicle-Controlled Clinical Trial of an Alpha and Beta Defensin-Containing Anti-Aging Skin Care Regimen With Clinical, Histopathologic, Immunohistochemical, Photographic, and Ultrasound Evaluation

April 2018 | Volume 17 | Issue 4 | Original Article | 426 | Copyright © April 2018

Amy Taub MD,a Vivian Bucay MD,b Gregory Keller MD,c Jay Williams PhD,c and Darius Mehregan MDd

aAdvanced Dermatology/Skinfo, Lincolnshire, IL; Northwestern University Medical School, Department of Dermatology, Chicago, IL bBucay Center for Dermatology and Aesthetics, San Antonio, TX cGregory Keller Plastic Surgery, Santa Barbara, CA dWayne State University, Monroe, MI

Figure 5Table 4in all three criteria at week 6 or week 12, no participants of 3 (0%) in the PG had such improvement (Table 5); the result was statistically significant (P=0.045). All 4 participants (100%) from the FFG who were randomly assigned to histopathological evaluation demonstrated an increase in the epidermal thickness and as well at least one grade improvement in ALL of the following: pores, hyperpigmentation, superficial, and deep wrinkles at week 6 or week 12 (Table 6). In contrast, zero participants of the PG (out of 3) who underwent histopathological evaluation, had improvement in all five parameters together (epidermal thickness, pores, hyperpigmentation, superficial, and deep wrinkles).This observation was also statistically significant (P=0.029). Site 3 had means of evaluation utilizing 3D LifeViz (QuantifiCare, France) and DermaLab® SkinLab Combo suite (Cortex Technologies, Denmark). The QuantifiCare analysis (12 subjects: 8 FFG and 4 PG) demonstrated a significant improvement in the score of “evenness” (Figure 9A; defined as the measurement of skin surface irregularity), as well as the score of “oiliness” (shiny parts of the skin, in association with pores, highlighting parts exhibiting sebum abnormalities; Figure 9B). These measurements were based on baseline values compared with week 12 in FFG vs PG: P values